Ovarian Cancer
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DS8201-772)
- Details
ClinicalTrials.gov ID:
NCT06819007
Diagnosis Type:
NA
USOR Number:
- Address
,
P: